The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Toxic Epidermal Neurolysis Drug Market Research Report 2024
Synopsis
Toxic epidermal neurolysis, or TEN syndromes, are rare, severe forms of Stevens-Johnson syndrome (SJS). SJS only causes skin to blister and peel on roughly 10% of the body. When between 10% and 30% of the body is covered, both situations exist. Every year, SJS, as well as TEN, together impact between 1 and 2 million people.
Global Toxic Epidermal Neurolysis Drug market is projected to reach US$ 11420 million in 2029, increasing from US$ 8415 million in 2022, with the CAGR of 4.1% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Toxic Epidermal Neurolysis Drug market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Toxic Epidermal Neurolysis Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Pfizer
Novartis
Sanofi
Merck and Co
Sun pharma
Abbott laboratories
Johnson & Johnson
Teva pharmaceuticals
Viatris
Segment by Type
Antibiotics
Corticosteroids
Intravenous Immunoglobulins
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Toxic Epidermal Neurolysis Drug report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Toxic epidermal neurolysis, or TEN syndromes, are rare, severe forms of Stevens-Johnson syndrome (SJS). SJS only causes skin to blister and peel on roughly 10% of the body. When between 10% and 30% of the body is covered, both situations exist. Every year, SJS, as well as TEN, together impact between 1 and 2 million people.
Global Toxic Epidermal Neurolysis Drug market is projected to reach US$ 11420 million in 2029, increasing from US$ 8415 million in 2022, with the CAGR of 4.1% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Toxic Epidermal Neurolysis Drug market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Toxic Epidermal Neurolysis Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Pfizer
Novartis
Sanofi
Merck and Co
Sun pharma
Abbott laboratories
Johnson & Johnson
Teva pharmaceuticals
Viatris
Segment by Type
Antibiotics
Corticosteroids
Intravenous Immunoglobulins
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Toxic Epidermal Neurolysis Drug report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Toxic Epidermal Neurolysis Drug Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Antibiotics
1.2.3 Corticosteroids
1.2.4 Intravenous Immunoglobulins
1.3 Market by Application
1.3.1 Global Toxic Epidermal Neurolysis Drug Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Toxic Epidermal Neurolysis Drug Market Perspective (2018-2029)
2.2 Toxic Epidermal Neurolysis Drug Growth Trends by Region
2.2.1 Global Toxic Epidermal Neurolysis Drug Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Toxic Epidermal Neurolysis Drug Historic Market Size by Region (2018-2023)
2.2.3 Toxic Epidermal Neurolysis Drug Forecasted Market Size by Region (2024-2029)
2.3 Toxic Epidermal Neurolysis Drug Market Dynamics
2.3.1 Toxic Epidermal Neurolysis Drug Industry Trends
2.3.2 Toxic Epidermal Neurolysis Drug Market Drivers
2.3.3 Toxic Epidermal Neurolysis Drug Market Challenges
2.3.4 Toxic Epidermal Neurolysis Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Toxic Epidermal Neurolysis Drug Players by Revenue
3.1.1 Global Top Toxic Epidermal Neurolysis Drug Players by Revenue (2018-2023)
3.1.2 Global Toxic Epidermal Neurolysis Drug Revenue Market Share by Players (2018-2023)
3.2 Global Toxic Epidermal Neurolysis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Toxic Epidermal Neurolysis Drug Revenue
3.4 Global Toxic Epidermal Neurolysis Drug Market Concentration Ratio
3.4.1 Global Toxic Epidermal Neurolysis Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Toxic Epidermal Neurolysis Drug Revenue in 2022
3.5 Toxic Epidermal Neurolysis Drug Key Players Head office and Area Served
3.6 Key Players Toxic Epidermal Neurolysis Drug Product Solution and Service
3.7 Date of Enter into Toxic Epidermal Neurolysis Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Toxic Epidermal Neurolysis Drug Breakdown Data by Type
4.1 Global Toxic Epidermal Neurolysis Drug Historic Market Size by Type (2018-2023)
4.2 Global Toxic Epidermal Neurolysis Drug Forecasted Market Size by Type (2024-2029)
5 Toxic Epidermal Neurolysis Drug Breakdown Data by Application
5.1 Global Toxic Epidermal Neurolysis Drug Historic Market Size by Application (2018-2023)
5.2 Global Toxic Epidermal Neurolysis Drug Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Toxic Epidermal Neurolysis Drug Market Size (2018-2029)
6.2 North America Toxic Epidermal Neurolysis Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Toxic Epidermal Neurolysis Drug Market Size by Country (2018-2023)
6.4 North America Toxic Epidermal Neurolysis Drug Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Toxic Epidermal Neurolysis Drug Market Size (2018-2029)
7.2 Europe Toxic Epidermal Neurolysis Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Toxic Epidermal Neurolysis Drug Market Size by Country (2018-2023)
7.4 Europe Toxic Epidermal Neurolysis Drug Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Toxic Epidermal Neurolysis Drug Market Size (2018-2029)
8.2 Asia-Pacific Toxic Epidermal Neurolysis Drug Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Toxic Epidermal Neurolysis Drug Market Size by Region (2018-2023)
8.4 Asia-Pacific Toxic Epidermal Neurolysis Drug Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Toxic Epidermal Neurolysis Drug Market Size (2018-2029)
9.2 Latin America Toxic Epidermal Neurolysis Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Toxic Epidermal Neurolysis Drug Market Size by Country (2018-2023)
9.4 Latin America Toxic Epidermal Neurolysis Drug Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Toxic Epidermal Neurolysis Drug Market Size (2018-2029)
10.2 Middle East & Africa Toxic Epidermal Neurolysis Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Toxic Epidermal Neurolysis Drug Market Size by Country (2018-2023)
10.4 Middle East & Africa Toxic Epidermal Neurolysis Drug Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Toxic Epidermal Neurolysis Drug Introduction
11.1.4 Pfizer Revenue in Toxic Epidermal Neurolysis Drug Business (2018-2023)
11.1.5 Pfizer Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Toxic Epidermal Neurolysis Drug Introduction
11.2.4 Novartis Revenue in Toxic Epidermal Neurolysis Drug Business (2018-2023)
11.2.5 Novartis Recent Development
11.3 Sanofi
11.3.1 Sanofi Company Detail
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Toxic Epidermal Neurolysis Drug Introduction
11.3.4 Sanofi Revenue in Toxic Epidermal Neurolysis Drug Business (2018-2023)
11.3.5 Sanofi Recent Development
11.4 Merck and Co
11.4.1 Merck and Co Company Detail
11.4.2 Merck and Co Business Overview
11.4.3 Merck and Co Toxic Epidermal Neurolysis Drug Introduction
11.4.4 Merck and Co Revenue in Toxic Epidermal Neurolysis Drug Business (2018-2023)
11.4.5 Merck and Co Recent Development
11.5 Sun pharma
11.5.1 Sun pharma Company Detail
11.5.2 Sun pharma Business Overview
11.5.3 Sun pharma Toxic Epidermal Neurolysis Drug Introduction
11.5.4 Sun pharma Revenue in Toxic Epidermal Neurolysis Drug Business (2018-2023)
11.5.5 Sun pharma Recent Development
11.6 Abbott laboratories
11.6.1 Abbott laboratories Company Detail
11.6.2 Abbott laboratories Business Overview
11.6.3 Abbott laboratories Toxic Epidermal Neurolysis Drug Introduction
11.6.4 Abbott laboratories Revenue in Toxic Epidermal Neurolysis Drug Business (2018-2023)
11.6.5 Abbott laboratories Recent Development
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Company Detail
11.7.2 Johnson & Johnson Business Overview
11.7.3 Johnson & Johnson Toxic Epidermal Neurolysis Drug Introduction
11.7.4 Johnson & Johnson Revenue in Toxic Epidermal Neurolysis Drug Business (2018-2023)
11.7.5 Johnson & Johnson Recent Development
11.8 Teva pharmaceuticals
11.8.1 Teva pharmaceuticals Company Detail
11.8.2 Teva pharmaceuticals Business Overview
11.8.3 Teva pharmaceuticals Toxic Epidermal Neurolysis Drug Introduction
11.8.4 Teva pharmaceuticals Revenue in Toxic Epidermal Neurolysis Drug Business (2018-2023)
11.8.5 Teva pharmaceuticals Recent Development
11.9 Viatris
11.9.1 Viatris Company Detail
11.9.2 Viatris Business Overview
11.9.3 Viatris Toxic Epidermal Neurolysis Drug Introduction
11.9.4 Viatris Revenue in Toxic Epidermal Neurolysis Drug Business (2018-2023)
11.9.5 Viatris Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
